The diphenylpyrazole compound anle138b blocks A beta channels and rescues disease phenotypes in a mouse model for amyloid pathology

Hernandez, Ana Martinez; Urbanke, Hendrik; Gillman, Alan L.; Lee, Joon; Ryazanov, Sergey; Agbemenyah, Hope Y.; Benito, Eva; Jain, Gaurav; Kaurani, Lalit; Grigorian, Gayane; Leonov, Andrei; Rezaei-Ghaleh, Nasrollah; Wilken, Petra; Arce, Fernando Teran; Wagner, Jens; Fuhrman, Martin; Caruana, Mario; Camilleri, Angelique; Vassallo, Neville; Zweckstetter, Markus; Benz, Roland; Giese, Armin; Schneider, Anja; Korte, Martin; Lal, Ratnesh; Griesinger, Christian; Eichele, Gregor and Fischer, Andre (2018): The diphenylpyrazole compound anle138b blocks A beta channels and rescues disease phenotypes in a mouse model for amyloid pathology. In: EMBO Molecular Medicine, Vol. 10, No. 1: pp. 32-47

Abstract

Alzheimer's disease is a devastating neurodegenerative disease eventually leading to dementia. An effective treatment does not yet exist. Here we show that oral application of the compound anle138b restores hippocampal synaptic and transcriptional plasticity as well as spatial memory in a mouse model for Alzheimer's disease, when given orally before or after the onset of pathology. At the mechanistic level, we provide evidence that anle138b blocks the activity of conducting Ab pores without changing the membrane embedded A beta-oligomer structure. In conclusion, our data suggest that anle138b is a novel and promising compound to treat AD-related pathology that should be investigated further.

• Item Type: Journal article
• Faculties: Medicine
• Subjects: 600 Technology > 610 Medicine and health
• ISSN: 1757-4676
• Language: English